复宏汉霖(02696.HK)与润新生物签订产品许可安排
复宏汉霖-B(02696.HK)公布,与与苏州润新生物订立具约束力条款概要。据此,公司获授予在中国开发、生产、商业化及再许可靶向人类BRAF蛋白V600E突变小分子抑制剂RX208的独家权利,公司须支付包括:首付款9,750万人民币、销售里程碑付款合计不超过10.78亿人民币以及年度净销售额的8%-12%计的特许权使用费。
许可产品或可能与集团管线中的生物药产生协同效应,进而增强集团在肿瘤治疗领域的综合市场竞争力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.